Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Prostate ; 78(2): 80-85, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29105796

RESUMO

BACKGROUND: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) involves inflammation of the prostate and affects the quality of life of men of all ages. It is well reported in clinical studies that the treatment for CP/CPPS using nonsteroidal anti-inflammatory drugs (NSAIDs) produced favorable outcomes. However, currently, there are no guidelines on choice of the NSAIDs for the treatment of CP/CPPS. Therefore, in the current research study, we evaluated the prostate tissue penetration of four NSAIDs in rats to provide guidance on choice of NSAIDs for the treatment of CP/CPPS. METHODS: Male Sprague-Dawley rats were administered orally with four NSAIDs viz. celecoxib, diclofenac, ibuprofen, and naproxen at 500 mg/kg dose. The animals were then sacrificed at various time points, and their prostate tissues were harvested. The NSAIDs were then extracted from the prostate tissues using liquid extraction technique, and their concentration in prostate tissue was quantified using high-performance liquid chromatography (HPLC). The prostate tissue penetration and related pharmacokinetic parameters were evaluated by non-compartmental analysis. RESULTS: The HPLC method for quantifying NSAIDs in prostate tissue resulted in single, sharp peaks without any interference and all validation parameters were within limits. Celecoxib showed the highest area under the curve (AUC) [146.50 ± 2.75 µg/mL*h] of all NSAID's. A two-factor analysis of variance (ANOVA) with replication indicated an overall statistically significant difference in the pharmacokinetic parameters for celecoxib, diclofenac, ibuprofen, and naproxen. CONCLUSIONS: This study for the first time reported the relative prostate tissue penetration of four NSAIDs. The pharmacokinetic data indicated that celecoxib has the highest penetration and retention in rat prostate tissues. Therefore, celecoxib may be considered as a better choice for the treatment CP/CPPS involving NSAIDs.


Assuntos
Celecoxib/farmacocinética , Diclofenaco/farmacocinética , Ibuprofeno/farmacocinética , Naproxeno/farmacocinética , Dor Pélvica , Próstata , Prostatite , Análise de Variância , Animais , Anti-Inflamatórios não Esteroides/farmacocinética , Área Sob a Curva , Cromatografia Líquida/métodos , Pesquisa Comparativa da Efetividade , Modelos Animais de Doenças , Inflamação , Masculino , Dor Pélvica/tratamento farmacológico , Dor Pélvica/metabolismo , Dor Pélvica/patologia , Próstata/efeitos dos fármacos , Próstata/metabolismo , Próstata/patologia , Prostatite/tratamento farmacológico , Prostatite/metabolismo , Prostatite/patologia , Ratos , Ratos Sprague-Dawley , Distribuição Tecidual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA